Table 5.

Summary of meta-analysis conducted by several groups for the treatment of COVID-19

S.N.	Therapeutic drug	Common name	Target	Comments/significance	References
1	Chloroquine derives hydroxy-chloroquine	Aralen/plaquenil	SARS-CoV 2	More useful to improve clinical and virological outcomes. But reduce mortality	Million et al. (2020), Pathak et al. (2020), Siemieniuk et al. (2020)
2	Dexamethasone	Decadron	SARS-CoV 2	Risk of mortality and benefits for severing clinical condition patients	Abeldano Zuniga et al. (2020), Siemieniuk et al. (2020)
3	Lopinavir-Ritonavir	Kaletra	HIV, SARS-CoV 2	Risk of mortality, adverse events	Abeldano Zuniga et al. (2020), Siemieniuk et al. (2020)
4	Remdesivir with placebo	Veklury	Ebola, COVID-19	Risk of mortality	Abeldano Zuniga et al. (2020), Siemieniuk et al. (2020)
5	Hydroxy-chloroquine with azithromycin	Aralen/plaquenil and zitromax	SARS-CoV 2	Not alter the rate of risk of virologic cure and risk of mortality, Not different from hydroxy-chloroquine alone	Ayele Mega et al. (2020), Chen et al. (2020c), (Tang et al. (2020), Fiolet et al. (2020), Abeldano Zuniga et al. (2020), Siemieniuk et al. (2020)
6	Tolicizumab	Actemra		Lower mortality was 12%	Malgie et al. (2020)
7	Convalescent Plasma	NA	SARS-CoV 2	Mortality and virological clearance	Abeldano Zuniga et al. (2020), Siemieniuk et al. (2020)
8	Vaccine vs placebo	NA	SARS-CoV 2	Significantly increase IgG level than placebo, total local events also changed (P > 0.05)	Yuan et al. (2020)